XML 92 R79.htm IDEA: XBRL DOCUMENT v3.24.3

SEGMENT INFORMATION - Summary of Financial Information for Our Segments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Net sales	$ 2,699	$ 2,599	$ 7,883	$ 7,634
United States
Segment Reporting Information [Line Items]
Net sales	1,500	1,467	4,340	4,300
International
Segment Reporting Information [Line Items]
Net sales	1,199	1,132	3,543	3,334
Operating Segments | Medical Products and Therapies
Segment Reporting Information [Line Items]
Net sales	1,342	1,258	3,893	3,691
Operating Segments | Healthcare Systems and Technologies
Segment Reporting Information [Line Items]
Net sales	752	744	2,167	2,218
Operating Segments | Pharmaceuticals
Segment Reporting Information [Line Items]
Net sales	588	580	1,768	1,652
Operating Segments | United States | Medical Products and Therapies
Segment Reporting Information [Line Items]
Net sales	762	709	2,164	2,087
Operating Segments | United States | Healthcare Systems and Technologies
Segment Reporting Information [Line Items]
Net sales	557	551	1,580	1,607
Operating Segments | United States | Pharmaceuticals
Segment Reporting Information [Line Items]
Net sales	178	195	566	550
Operating Segments | International | Medical Products and Therapies
Segment Reporting Information [Line Items]
Net sales	580	549	1,729	1,604
Operating Segments | International | Healthcare Systems and Technologies
Segment Reporting Information [Line Items]
Net sales	195	193	587	611
Operating Segments | International | Pharmaceuticals
Segment Reporting Information [Line Items]
Net sales	410	385	1,202	1,102
Operating Segments | Infusion Therapies and Technologies | Medical Products and Therapies
Segment Reporting Information [Line Items]
Net sales	1,070	1,003	3,081	2,918
Operating Segments | Infusion Therapies and Technologies | United States | Medical Products and Therapies
Segment Reporting Information [Line Items]
Net sales	613	570	1,718	1,654
Operating Segments | Infusion Therapies and Technologies | International | Medical Products and Therapies
Segment Reporting Information [Line Items]
Net sales	457	433	1,363	1,264
Operating Segments | Advanced Surgery | Medical Products and Therapies
Segment Reporting Information [Line Items]
Net sales	272	255	812	773
Operating Segments | Advanced Surgery | United States | Medical Products and Therapies
Segment Reporting Information [Line Items]
Net sales	149	139	446	433
Operating Segments | Advanced Surgery | International | Medical Products and Therapies
Segment Reporting Information [Line Items]
Net sales	123	116	366	340
Operating Segments | Care and Connectivity Solutions | Healthcare Systems and Technologies
Segment Reporting Information [Line Items]
Net sales	456	443	1,310	1,307
Operating Segments | Care and Connectivity Solutions | United States | Healthcare Systems and Technologies
Segment Reporting Information [Line Items]
Net sales	335	317	945	926
Operating Segments | Care and Connectivity Solutions | International | Healthcare Systems and Technologies
Segment Reporting Information [Line Items]
Net sales	121	126	365	381
Operating Segments | Front Line Care | Healthcare Systems and Technologies
Segment Reporting Information [Line Items]
Net sales	296	301	857	911
Operating Segments | Front Line Care | United States | Healthcare Systems and Technologies
Segment Reporting Information [Line Items]
Net sales	222	234	635	681
Operating Segments | Front Line Care | International | Healthcare Systems and Technologies
Segment Reporting Information [Line Items]
Net sales	74	67	222	230
Operating Segments | Injectables and Anesthesia | Pharmaceuticals
Segment Reporting Information [Line Items]
Net sales	321	351	990	987
Operating Segments | Injectables and Anesthesia | United States | Pharmaceuticals
Segment Reporting Information [Line Items]
Net sales	178	195	566	550
Operating Segments | Injectables and Anesthesia | International | Pharmaceuticals
Segment Reporting Information [Line Items]
Net sales	143	156	424	437
Operating Segments | Drug Compounding | Pharmaceuticals
Segment Reporting Information [Line Items]
Net sales	267	229	778	665
Operating Segments | Drug Compounding | United States | Pharmaceuticals
Segment Reporting Information [Line Items]
Net sales	0	0	0	0
Operating Segments | Drug Compounding | International | Pharmaceuticals
Segment Reporting Information [Line Items]
Net sales	267	229	778	665
Other
Segment Reporting Information [Line Items]
Net sales	17	17	55	73
Other | United States
Segment Reporting Information [Line Items]
Net sales	3	12	30	56
Other | International
Segment Reporting Information [Line Items]
Net sales	$ 14	$ 5	$ 25	$ 17

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=bax_MedicalProductsAndTherapiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=bax_HealthcareSystemsAndTechnologiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=bax_PharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bax_InfusionTherapiesAndTechnologiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bax_AdvancedSurgeryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bax_CareAndConnectivitySolutionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bax_FrontLineCareMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bax_InjectablesAndAnesthesiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=bax_PharmaceuticalCompoundingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: